A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.

In an apparatus and method of manufacturing a multi-column multi-medicine oral dissolving film according to the present invention, all processes from film feeding, medicine coating, and medicine drying to product packaging are implemented as continuous automation processes, and under the automation processes, different kinds of medicines are coated on a base film in multiple columns in a signal layer by using a plurality of nozzles supplied with the different kinds of medicines, so that it is possible to improve productivity through the automation processes, to ensure product quality due to efficiency during drying caused by maintaining the thickness of the product, and to provide a convenience in the case of taking various kinds of small-amount medicines at one time or in the case of separately and selectively taking different kinds of medicines.

Disclosed are: a composition for forming a complex; a complex formed therefrom; and a composition for oral ingestion, containing the same. The disclosed composition for forming a complex contains a cellulose-based compound, a polyphenolic compound, a gelling agent, and a solvent.

Hot melt extrusion is disclosed as a process for forming vaginal drug delivery films. The methods involve extruding a composition comprising one or more active pharmaceutical ingredients and one or more polymer carriers at an elevated temperature through a die to thereby provide the film. Films prepared by hot melt extrusion are also described.

A plastic material for extended release of a bio-active agent, the plastic material comprising a structural polymer, at least one bio-active ingredient embedded within the structural polymer as solid islands, a liquid binding material embedded within the structural polymer as granules, and a carrier liquid absorbed within the liquid-absorbent material. The carrier liquid may be sufficiently non-compatible with the structural polymer so that at least a portion of the carrier liquid is released from the liquid-absorbent material through the structural polymer to an outer surface of the plastic material over a period of time, such as a week or more, a month or more, or about three months. The bio-active agent comprised in the at least one bio-active ingredient may be sufficiently soluble in the carrier liquid at room or body temperature so that the carrier liquid released to the outer surface comprises the bio-active agent in solution.

The invention relates to a method for producing an active substance laminate, especially an oral active substance laminate (100), having at least one active-substance-containing layer (31), which is arranged on a substrate (20), wherein the method comprises the following steps: a) providing a substrate (20) having an upper side (21) and an underside (22); b) applying an active-substance-containing mass (24) in a gap (25) formed by a first rotating roller (26) and a second rotating roller (27); c) transporting the substrate (20) to the second roller (27) by means of a third rotating roller (28) in such a way that the active-substance-containing mass (24) is applied to the upper side (21) of the substrate (20) by the second roller (27) in the form of an active-substance-containing layer (31); d) transporting an intermediate laminate (30), formed by the substrate (20) and the active-substance-containing layer (31), to a drying device (40); and e) drying the intermediate laminate (30), especially the active-substance-containing layer (31).

A treatment solution includes a carrier liquid, and an antifungal agent comprising on of tolnaftate, terbinafine hydrochloride, and miconazole nitrate, the antifungal agent having a concentration of at least 1 wt % of the solution, wherein the treatment solution is alcohol free.

The present invention provides for an oral dissolvable film and a method of manufacturing and using the same.

The present invention provides an adhesive sheet for skin, which shows sufficient adhesiveness to the skin and causes low skin irritation.

The first adhesive sheet for skin of the present invention has an adhesive layer formed on a support, wherein the aforementioned adhesive layer contains at least a thermoplastic elastomer, non-volatile hydrocarbon oil and polyisobutylene having a viscosity average molecular weight of more than 100,000 and not more than 500,000, and does not contain a tackifier.

The second adhesive sheet for skin of the present invention has an adhesive layer formed on a support, wherein the aforementioned adhesive layer contains at least a thermoplastic elastomer, and more than 120 parts by weight and not more than 800 parts by weight of non-volatile hydrocarbon oil per 100 parts by weight of the elastomer, and more than 3 parts by weight and not more than 500 parts by weight of polyisobutylene, the polyisobutylene is a mixture of a low molecular weight polyisobutylene having a viscosity average molecular weight of more than 30,000 and not more than 100,000, and a high molecular weight polyisobutylene having a viscosity average molecular weight of more than 500,000 and not more than 5,000,000, and a tackifier is not contained.

Furthermore, a percutaneous absorption preparation containing a drug or a pharmaceutically acceptable salt thereof in an adhesive layer of the above-mentioned adhesive sheet for skin is provided.

A treatment solution contains a topical anesthetic, an anesthetic solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A treatment solution contains an antifungal agent, a topical anesthetic, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A treatment solution contains a topical anesthetic, an anesthetic solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 15 wt% or below of the total solution. A treatment solution contains an antifungal agent, a topical anesthetic, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 15 wt% or below of the total solution.